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Abstract: Peptides and proteins are becoming increasingly
valuable as medicines, diagnostic agents and as tools for
biomedical sciences. Much of this has been underpinned by
the emergence of new methods for the manipulation and
augmentation of native biomolecules. Perfluoroaromatic
reagents are perhaps one of the most diverse and exciting
tools with which to modify peptides and proteins, due
principally to their nucleophilic substitution chemistry, high
electron deficiency and the ability for their reactivity to be
tuned towards specific nucleophiles. As discussed in this
minireview, in recent years, perfluoroaromatic reagents have
found applications as protecting groups or activating groups
in peptide synthesis and as orthogonal handles for peptide
modification. Furthermore, they have applications in chemo-
selective ‘tagging’, stapling and bioconjugation of peptides
and proteins, as well as tuning of ‘drug-like’ properties. This
review will also explore possible future applications of these
reagents in biological chemistry.
1. Introduction
Interest in peptides has increased significantly over recent
decades, largely due to recognition of their potential therapeu-
tic applications in combination with a growing tendency for
drug-discovery to move away from small flat compounds.
Peptides can be highly potent and target-selective APIs, with
improved safety profiles over traditional small molecules and
this has seen them find increasing clinical approval rates across
a range of medical areas.[1] Consequently, methodologies to
access unnatural peptide architectures or to conduct late-stage
modification of peptides for example, to enhance drug-like
properties, has become increasingly important.[2] A major
challenge in peptide drug development is their sensitivity
towards enzymatic degradation, potentially diminishing their
efficacy. Indeed, the introduction of modifications and unnatu-
ral residues has shown that this propensity for enzymatic
degradation can be subverted.[3] In addition, late-stage mod-
ification or bioconjugation approaches mean that large libraries
of structurally diverse peptides can be readily accessed from a
common starting peptide, thus, greatly reducing time taken for
drug screening.[4]
Perfluoroaromatic and perfluoroheteroaromatic compounds
(all hydrogen atoms replaced by fluorine) have become an
increasingly popular tool in peptide modification and synthesis.
This is for good reason, perfluoroaromatic compounds have
been shown to be highly versatile moieties, participating in a
range of transformations, and possessing highly unusual
chemical properties themselves. Perfluoroaromatic compounds
are well known to undergo aromatic substitution reactions with
a variety of nucleophiles.[5] Due to the electron withdrawing
nature of several fluorine atoms, the aromatic rings within
perfluoroaromatic compounds are extremely electron-poor. This
lack of electron density in the π framework in combination with
the ability of flourines to act as leaving groups means that SNAr
processes are highly favoured. This has led perfluoroaromatics
to be used as protecting groups,[6] for bi-aryl modification,[7]
macrocycle synthesis[8] and in polymer chemistry,[9] where
highly controllable reactions are advantageous. The propensity
to react with nucleophiles makes this class of compound a
perfect candidate for peptide modification and bioconjugation.
This review provides a companion piece to the excellent
general reviews of arylation and conjugation of peptides.[10] It
presents an up-to-date synopsis of the uses of perfluoroar-
omatic and perfluoroheteroaromatic compounds in unnatural
amino acid synthesis, peptide modification and bioconjugation.
It looks to highlight a range of synthetic methodologies that
have been developed to incorporate perfluoroaryl functionality
into peptides and also the ways in which perfluoroaryl groups
have been used as reactive handles for further peptide
modifications. Finally, some future directions are discussed.
2. Peptide Synthesis
Perfluoro(hetero)aromatic moieties can be incorporated into
peptides through the synthesis of bespoke perfluoroarylated
building blocks. This section will discuss the routes to
incorporate perfluoroaromatic groups into amino acids and
their subsequent incorporation into peptides.
2.1. Synthesis of perfluoroarylated building blocks
The propensity for perfluoroaromatics to undergo SNAr proc-
esses lends itself to amino acid synthesis through a substitution
approach with amino acids that contain nucleophilic side
chains. The first use of this strategy was reported by Cobb and
co-workers in 2013, in which a O-(4-tetrafluoropyridyl)-serine
was prepared in 30% yield by treatment of a protected serine
with pentafluoropyridine (PFP) 2 (Scheme 1).[11] N-terminal
solution phase peptide coupling was then demonstrated in a
two-step sequence with Boc-Ala-OH in 78% overall yield. A
second amino acid was synthesised this time using a Boc/
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benzyl ester protected serine 6 in 55% yield. Benzyl depro-
tection, N-terminal elongation, followed by coupling with Boc-
Ala-OH was carried out to give the tripeptide 9 in 90% overall
yield.
This report was followed up on in 2019,[6] as part of a larger
study on the use of tetrafluoropyridyl moieties as protecting
groups for phenols for example tyrosine (Scheme 2). Boc-Tyr-
OMe 10 was treated with PFP 2 in the presence of potassium
carbonate to generate the tetrafluoropyridyl-appended amino
acid 11 in 75% yield. It was demonstrated that this perfluor-
oheteroaromatic tyrosine was compatible with peptide syn-
thesis. Subsequent Boc deprotection followed by coupling with
Boc-Ala-OH successfully generated dipeptide 13 in 94% yield.
This finding shows that the attachment of fluoropyridyl
moieties to tyrosine is reversible and this could be of interest in
peptides where dynamic properties are desirable.
Another amino acid that contains a nucleophilic group is
hydroxyproline (Hyp) and in 2013 Zondlo and co-workers
published an extensive report on 4-substituted prolines and
their effects on peptide conformation.[12] Substituted prolines
have been demonstrated to influence the conformation of the
proline ring itself. For example, 4-fluoroprolines have been
show induce ring pucker through a gauche effect due to the
electron-withdrawing effect of the fluorine, highly influencing
the endo/exo ring equilibrium and, therefore, the prolyl cis-trans
populations. In order to understand how 4-position subsitution
can have dramatic effects on proline ring and peptide
conformation, Zondlo and co-workers prepared a vast library of
substituted prolines. As part of this study a Mitsunobu approach
on solid phase was developed and applied to a range of
nucleophiles (Scheme 3). Using this approach short peptides
containing pentafluoroaryl ethers were synthesised (R,S)-16 and
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Scheme 1. Synthesis of a tetrafluoropyridine-containing amino acid and a
tripeptide.
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(S,S)-16. Taking advantage of the spin active nature of fluorine-
19 as a highly sensitive NMR-active nuclei, Zondlo was able to
employ the technique to measure the prolyl bond cis/trans
ratio.
Teegardin and Weaver developed methodology to perfluor-
oarylate and then ring-open oxazolones to access perfluoroar-
omatic amino acids where the perfluoroaryl group is attached
directly to the amino acid α-carbon back bone (Scheme 4).[13]
Treating 2-phenyloxazol-5(4H)-one 17 with the desired perfluor-
oaromatics 18 in the presence of base led to arylation of the
oxazolone, which was predisposed to ring opening. This could
then be esterified with catalytic TFA in dry alcohol to give the
protected amino acids 19a–19c. By modification of the
esterification procedure by using aqueous HCl the free carbox-
ylic acids 20a–20c were obtained. As part of the study, it was
demonstrated that the methodology was also applicable to C4
substituted oxazolones to generate amino acids with quater-
nary carbon centres and a range 21a–21c of protected amino
acids were isolated.
In 2017 Herrmann and co-workers disclosed the synthesis of
bi-aryl amino acids with perfluoroaryl functionalities
(Scheme 5).[14] Cross-coupling methodologies have become the
cornerstone in the synthesis of bi-aryl amino acids and in
Herrmann’s report, a Suzuki cross-coupling approach was
taken.[15] By treatment of compound 22 with [Pd(PiPr3)2] a highly
active catalyst (24) was formed, this in combination with
Scheme 2. Synthesis, deprotection and peptide coupling of a tetrafluoropyr-
idyl tyrosine amino acid.
Scheme 3. Synthesis of pentafluoroaryl-ether prolines on solid phase using a
Mitsunobu approach.
Scheme 4. Synthesis of perfluoroaryl amino acids.
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caesium fluoride allowed cross-coupling to occur to access
highly fluorinated bi-aryl amino acids 25a and 25b.
2.2. Applications of perfluoroaryl groups in further
functionalisation
The highly electron-poor nature of perfluoroaryl groups affords
their ability to stabilise anions and act as good leaving groups.
For example, pentafluorophenyl esters are very reactive towards
nucleophiles, allowing for nucleophilic substitution reactions to
be conducted under mild conditions. Therefore, pentafluoro-
phenyl esters have been employed to generate amides,[16]
esters[17] and cross-coupling products.[18] Due to the mild
conditions this approach has seen much use in the synthesis
and modification of peptides and bio-scaffolds.
Pentafluorophenyl esters are applicable to solid phase
peptide synthesis and this was first demonstrated by Atherton
and Sheppard in 1985 (Figure 1).[19] By using preformed Fmoc-
amino acid pentafluorophenyl esters 26 they were able to
synthesise the acyl carrier protein 65–74. They found that the
use of DMF and HOBt led to facile amide bond coupling and
allowed the preparation of the desired decapeptide with the
crude peptide displaying high purity (>90%). In 1987 a follow-
up was published by Sheppard and co-workers, which focused
on optimisation of reaction conditions to use Fmoc-amino acid
pentafluorophenyl esters on solid phase.[20] Using the decapep-
tide 27 and dodecapeptide 28 a range of reactions and
conditions were trialled. It was found that pentafluorophenyl
esters were easy to prepare for the vast majority of Fmoc-amino
acids (apart from Ser(tBu)-OH and Thr(tBu)-OH) and were easy-
to-handle crystalline solids. For amide coupling using DMF as
solvent and with HOBt as a catalyst. This first report laid the
bedrock for which others would build upon in other uses of
fluorophenyl esters in peptide modification.
In 2021, it was reported that pentafluoropyridine can also
be employed to synthesise amide bonds.[21] By mixing a
carboxylic acid with pentafluoropyridine it was shown that the
corresponding acyl fluoride could be readily generated. By
subsequent addition of an amine, the amide could be
generated in good to excellent yield across a wide range of
examples.
An example of the use of pentafluorophenyl esters in
peptide conjugation was reported by Klok and co-workers in
2011 (Scheme 6).[22] Employing a pentafluorophenyl ester in
atom transfer radical polymerisation (ATRP) gave a poly
(pentafluorophenyl methacrylate) polymer, which was subse-
quently modified to give the allyl appended polymer 31. This
polymer was then used in a thiol-ene “click” reaction to attach a
peptide to make a highly defined peptide-polymer conjugate
32. Such conjugates have many applications in, for example,
“smart” materials and in peptide drug delivery.
In 2012 Baltzer and co-workers reported the synthesis of
mixed pentafluorophenyl and ortho-fluorophenyl esters and
their use in peptide modification (Scheme 7).[23] By employing
two different fluorophenyl esters it was possible to obtain
sequential amide bond formations due to the differences in
reactivity. By mixing the mixed ester 35 with peptide 34 in the
presence of base the conjugate 36 was isolated in 84% yield.
Using the ortho-fluorophenyl ester-peptide 36 they were then
able to conduct a second peptide-conjugation reaction to
access large multi-component peptides.
Apart from being used as leaving groups for nucleophilic
substitution reactions, perfluoroaromatics have been used to
access dehydro-amino acids (Scheme 8). Webster et al. demon-
strated that the treatment of threonine with pentafluoropyr-
idine afforded N-tetrafluoropyridyl-dehydrobutyrine 38, via an
E1cb-type mechanism.[24]
3. Peptide Modification Using
Perfluoroaromatic Reagents
The SNAr arylation of peptide side chain nucleophiles by
perfluoroaromatics provides a route to install a useful chemical
handle for further chemical modification and for the trans-
Scheme 5. Synthesis of bi-aryl amino acids.
Figure 1. Synthesis of peptides on solid phase using pentafluorophenyl
esters.
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formation of linear unstructured short peptides into defined
secondary structures for example macrocycles and helices.
These specific applications depend on the nature of the
perfluoro(hetero)aromatic reagent and its particular SNAr reac-
tivity profile.
3.1. Peptide perfluoroarylation
Perfluoroheteroaromatics for example pentafluoropyridine tend
to have broad reactivity towards nucleophiles in polar organic
solvents (e.g. DMF) and reaction with unprotected peptides can
afford multiple arylation products at, for example, cysteine
thiols, tyrosine hydroxyl groups and free amines; whilst the less
reactive hexafluorobenzene (40) tends to only react with
cysteine thiols under mild conditions (Scheme 9).[25] Used in
excess, tetrafluoropyridazine (more electrophilic than penta-
fluoropyridine 2) was found to afford complete arylation of
tyrosine and the peptide N-terminus in the ‘tagging’ of
oxytocin. This was shown to increase resistance to chymotryp-
sin hydrolysis.[25]
The reactivity and chemoselectivity of pentafluoropyridine 2
can be controlled by the use of 2,2,2-trifluoroethanol as a
solvent, affording mild and clean reaction of pentafluoropyr-
idine with cysteine residues in the presence of unprotected free
amines and phenols (e.g. Lys, Tyr), whilst hexafluorobenzene
was unreactive under these conditions.[26] This was presumed to
be due to the ability of TFE to solvate O- and N-centered
nucleophiles, reducing their apparent nucleophilicity over larger
diffuse thiols. Alternatively, the reduction in the reactivity of the
hexafluorobenzene/pentafluoropyridine in TFE (compared with
DMF) could also be due to the Meisenheimer-Jackson inter-
mediate not being significantly stabilised during the SNAr
arylation reactions.
The Diness Group, explored the reactivity and selectivity of
SNAr reactions between fluorobenzene derivatives and bio-
logically relevant nucleophiles by a ‘two dimensional rational
tuning’ approach.[27] By altering the electron-withdrawing ability
of a phenyl para-substituent and the number of fluorine atoms
attached to the phenyl ring, reactivity towards (N-Boc)-Cys-OH
was probed in either, phosphate buffered saline (PBS) and
acetonitrile at various pHs, or in a mixture of DMF and N,N’-
diisopropylethylamine (DIPEA). In general, the reactivity was
found to be sensitive to the electron donating/withdrawing
nature of the para-substituent, and removal of fluorine atoms
from the ring attenuated the reactivity. This led to the design of
a highly reactive pentafluorophenyl sulfonamide 42a (Figure 2)
that was found to be selective for cysteine arylation over other
competing amino acids in a model peptide. Indeed, a further
analogue 42b containing PEG-azide (Figure 2) was shown to
selectively label enhanced green fluorescent protein (eGFP) and
Scheme 6. Synthesis of peptide appended polymers.
Scheme 7. Peptide conjugation using fluorophenyl esters.
Scheme 8. Synthesis of dehydrobutyrine derivatives.
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human serum albumin, allowing fluorescent labelling; whilst
reactivity-tuned variants could also covalently label and inhibit
cysteine proteases over serine proteases (at cysteine thiols) in a
site-selective and activity-dependent (only when fully folded)
manner.
Alapour and co-workers investigated a reverse strategy -
incorporating the perfluoroaryl group into the peptide back-
bone for subsequent SNAr functionalisation (Scheme 10).
[28]
Here, they studied reactivity and site specificity of pentafluoro-
acetic acid and pentafluorothiophenol (attached via an iodoace-
tamide precursor) as useful new perfluoroaromatic linkers for
on-resin peptide diversification and demonstrated that these
linkers are of approximately equivalent reactivity and can
undergo SNAr reaction with a range of nucleophiles (S-, N- and
O-centred) using NMP as a solvent and DBU as a base in a
relatively short (1 h) reaction time. Multiple ortho- and para-
substitutions were observed with some thiol nucleophiles,
which gives access to a possible new strategy for peptide
branching and dendrimer preparation.
3.2. Peptide stapling and macrocyclisation
Constraining linear peptides into defined secondary structures
through macrocyclization or ‘stapling’, has become a leading
area for research into new bioactive drug modalities. Macro-
cyclic/stapled peptides can access previously ‘undruggable’
targets with increased affinity, cellular penetration and resist-
Scheme 9. General approaches to controlling peptide perfluoroarylation.
Figure 2. Compounds employed for selective labelling experiments.
Scheme 10. On-resin approaches to peptide N-terminal conjugation or dendrimer formation via perfluoroarylation. Based on Ref. [28].
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ance to proteolytic breakdown, and this has stimulated
significant interest into new mild and regio-/chemoselective
ways to obtain such architectures.[2d,29]
Hexafluorobenzene, is of relatively intermediate reactivity,
but unlike pentafluoropyridine, readily undergoes successive
regioselective 1, 4-disubstituion (SNAr) reactions (Scheme 11),
[5]
particularly with thiolate nucleophiles. This makes it a useful
reagent for disulfide cross-linking chemistry in peptide and
protein systems.[30] The incorporation of two cysteine residues
with relative i and i + 4 spacing into a peptide with a tendency
to adopt an α-helical conformation preorganises the thiolates
on the same face of the helix. In basic buffer solution,
hexafluorobenzene undergoes chemoselective two-component
cross-linking of α-helical peptides, and the resulting stapled
peptides exhibited increased helicity and resistance to proteo-
lytic degradation.
Decafluorobiphenyl (47) behaves similarly to hexafluoroben-
zene, undergoing a regioselective 4, 4‘-double thiol-fluoride
substitution (Scheme 11), and providing a longer crosslinking
motif, well suited to i, i + 7 disulfide crosslinking.[30] Interestingly,
the perfluoroaryl crosslinking of disulfides in transportan-10[31]
and Pt(IV) prodrug peptides for glioblastoma treatment[32] was
also found to increase blood-brain barrier penetration in
models, and may be utilised in future for improved targeting of
notoriously challenging CNS targets.
Hexafluorobenzene and related thiol-substituted pentafluor-
ophenyl reagents have also been utilised in the side chain
macrocyclization of non-helical peptides, directly cross-linking
reduced disulfides (from i, i +1 to i, i +14) in an analogous
manner to the above.[33] In addition, a reverse approach was
demonstrated, in which each cysteine was individually arylated
(monosubstitution) with a non-bridging perfluoroaryl group
and then commercially available dithiol linkers were used for
subsequent macrocyclization to afford diverse peptide libraries
(Scheme 12).
This transformation has since been employed in several
different peptide systems under related conditions, typically
employing DMF as solvent and either TRIS-base, Et3N or DIPEA
as base, with reaction times ranging from 30 min up to 18 h.[34]
In one example, the reaction of hexafluorobenzene 40 with N-
acetyl cysteine was explored and optimised using a 2-level
factorial design experiment (varying: reaction time, temper-
ature, concentration and equivalents of base/thiol) and mon-
itoring the reaction outcomes by the distinct spectra obtained
using 19F NMR analysis of crude mixtures.[35] Application of the
Scheme 11. General approaches to two-component peptide stapling by
perfluoroaromatic reagents.
Scheme 12. General approaches to peptide macrocyclisation using perfluoroaromatic-based reagents. Note, peptide sequences shown are for illustrative
purposes only. Based on Refer. [33].
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optimal mild conditions (DMSO/Cs2CO3, 21 °C or MeCN/DBU,
21 °C) to a model unprotected peptide system rapidly (<
1 minute and <1 h, respectively,) afforded the quantitative
disubstitution (stapled) product. The reaction was also possible
on-resin (DMF, DIPEA, 21 °C, 18hours), making this applicable to
solid phase modification.
The thiol-fluoride substitution reaction also proceeds
smoothly using cysteine ‘analogues’, including homocysteine
and penicillamine, albeit with differing reaction rates relative to
cysteine. In this case, a reported peptide inhibitor of the p53-
MDM2 and p53-MDMX protein-protein interaction was mutated
to incorporate combinations of L-Cys, D-Cys, L-Pen and hCys to
subtly tune the binding affinity and target-selectivity by altering
the secondary structure.[36] Perfluoroaromatics (no nitrogen
atoms in the ring) tend to be cysteine-selective in their
reactivity, however, the crosslinking of lysine amines is made
possible (Scheme 11) by increasing the electron-deficiency
through using activated perfluoroaryl reagents for example
diperfluorophenyl sulfone (48).[37]
Despite exhibiting excellent chemoselectivity, the site
selectivity of fluorarylation is expected to be relatively non-
specific where the peptide system contains >2 cysteine
residues lacking appropriate protecting groups or pre-organ-
isation. However, regiocontrol can be achieved by the incorpo-
ration of a ‘glutathione tag’ (γ-Glu-Cys-Gly), that primes the
peptide for regioselective fluoroaryl macrocyclisation mediated
by a glutathione-S-transferase (GST) enzyme (Scheme 13).[38]
3.3. Reagents for site-selective bioconjugation
Site-selective protein modification allows biomolecules such as
monoclonal antibodies with high-target selectivity, to be
conjugated with otherwise indiscriminately cytotoxic agents, to
afford tissue-targeted and selective agents for for example
cancer treatment.[39] Besides antibody-drug conjugates, the
ability to selectively attach bioactives to long-lived plasma
proteins or to attach fluorescent probes has transformed
modern approaches to medicine.[40]
Protein labelling or bioconjugation is generally performed
using cysteine-selective reagents, such as maleimides.[41] As
discussed above, many perfluoroaromatics are highly suscep-
tible to double substitution in a 1,4- or 4,4’- manner due to the
increased stabilisation of the Meisenheimer-Jackson intermedi-
ate by the sulfur atom from the first substitution. If only a single
thiol nucleophile is available or a high excess of the perfluor-
oaryl reagent is used, a singly arylated product can be obtained
(Scheme 14). This makes mono-substituted perfluoroaromatics
well suited as highly chemoselective bioconjugating reagents.
The main challenge associated with modification/conjuga-
tion of large polypeptides is reacting at the desired site when
multiple chemically similar reactive handles are available.
Another limitation of the methods described above is their
requirement for an organic solvent, which is incompatible with
biomolecules, whilst the reaction is also be hindered by the
slow SNAr reactivity of perfluoroaromatics in water. As we have
seen earlier for perfluoroaryl macrocyclization, these challenges
can be overcome by incorporating an N-terminal glutathione
(γ-Glu-Cys-Gly) recognition-sequence into peptides, whose
monoarylation is specifically promoted at the glutathione
cysteine in the presence of a glutathione-S-transferase
enzyme.[42]
Site-/regioselectivity can also be obtained in an enzyme-
independent manner through the use of a ‘π-clamp’ approach
(Scheme 15). This incorporated a Phe-Cys-Pro-Phe motif into a
peptide, which promoted the selective reaction of the cysteine
residue with perfluoroaromatic reagents (aqueous conditions,
<1 h.[43] Molecular dynamics (MD) modelling and density func-
tional theory (DFT) proposed that the accelerated reaction rate
at the FCPF motif was due to the π-clamp providing a
microenvironment that mimics an enzyme active-site and tunes
the reactivity of the cysteine by reducing the thiol pKa,
recognising the perfluoroaromatic reaction partner and de-
creasing the enthalpy of activation for the SNAr reaction.
[44]
The π-clamp approach was used to modify the C-terminus
of the heavy chains of trastuzumab (monoclonal antibody used
in breast cancer treatment)[45] enabling the synthesis of site-
specific antibody-drug conjugates (Scheme 15) that retained
binding affinity to their targets for selective killing of BT474
HER2-positive breast cancer cells.[43] The first non-terminal
location for the π-clamp motif, was demonstrated in the
investigation of the assembly of the major capsid protein of the
JC polyomavirus, the causative agent of progressive multifocal
leukoencephalopathy (PML).[46] Recombinant truncated VP1
Scheme 13. Site-selective peptide macrocyclisation promoted by a glutathione tag in the presence of a glutathione S-transferase. Note, peptide sequences
shown are for illustrative purposes only. Based on Ref. [38].
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pentamers were prepared containing the π-clamp motif (FCPF)
in a non-conserved and surface-exposed mid-sequence loop.
This was found to be site-selectively labelled using a modular
probe 57 (Figure 3), in which nonafluorobiphenyl was linked by
a triethyleneglycol spacer to an azide for CuAAC reaction with a
variety of small molecule cargoes for example fluorophores.
The aqueous, biocompatible arylation reaction rate can also
be controlled by adding salts, increasing rates by up to 4 orders
of magnitude according to the Hoffmeister ions series, wherein
for example ammonium sulfate is known to promote hydro-
phobic interactions and accelerates the bioconjugation of a
model antibody in a concentration-dependent manner.[47]
In a bid to understand the wider sequence effects on
cysteine-arylation and to discover cysteine-containing polypep-
tide sequences with an intrinsic propensity to react with
perfluoroaromatics, Evans et al. screened a library of random
sequence ~30-mer peptides using mRNA display and high-
throughput sequencing.[48] They identified a 29 amino acid
peptide (MP01) (not containing the FCPF sequence) that had an
intrinsically favourable rate of arylation (0.28 M  1 s  1 at pH 7.4
and room temperature), and therefore, underwent site-selective
cysteine arylation, with a water-soluble perfluorodiphenyl
sulfide-based reagent, and afforded selective arylation in
protein fusion constructs. Perfluoroaryl reagents were found to
interact with MP01 (and related peptides) in an initial non-
covalent fashion (similarly to the π-clamp), increasing the
effective molarity and thus the reaction rate in analogy to
enzymes.[49] The arylation rate also appeared to be enhanced by
the perfluoroaryl reagent-inducing increased α-helical character
of the cysteine-containing peptide indicating that the secon-
dary structure of the nucleophilic species affects the reaction
rate and site-selectivity. Indeed, these observations appear to
be general and applicable to a broad family of cysteine-
containing peptides, many of which adopt secondary structures
(including β-sheets) as part of the arylation process.[50] As such,
Scheme 14. Site-selective peptide or protein arylation as a means of bioconjugation with a prefunctionalised perfluoroaryl probe. Note, peptide sequences
shown are for illustrative purposes only. Based on Ref. [42].
Scheme 15. π-clamp mediated site-selective cysteine bioconjugation. The accelerated rate has been attributed to interactions between the Phe residues and
the incoming perfluoroaromatic, as well as increasing Cys acidity. Based on Ref. [43].
Figure 3. Molecular probe designed for efficient conjugation using the π-
clamp approach.
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the authors proposed that the arylation reaction is dependent
on the folded 3D structure of the peptide (and ablated by
denaturation), in analogy to an enzyme active site.
3.4. Construction of multicyclic peptide systems
The construction of multicyclic peptide architectures through
the reaction of tri-/tetra-cysteine containing peptides with tri-/
tetra-bromomethyl benzene electrophiles and related
reagents[51] has revolutionised the screening of peptides
displaying 3D protein epitope-like features. Typically, these
methods afford a mixture of regioisomers due to the identical
reactivity of each electrophilic site. Bicyclic systems can
conceptually be prepared by double perfluoroaryl-macrocyclisa-
tion at two cysteine pairs (Scheme 16 (A)), however, this
requires orthogonal protecting group shuffling to avoid multi-
ple regioisomeric products. In an extension of earlier method-
ology, another way to obtain bicyclic peptides was achieved via
perfluoroarylation of three separate cysteines with decafluor-
obiphenyl (mono-substitution) to afford the tri-arylated peptide,
which is primed to undergo three secondary substitution
reactions with 1,3,5-benzenetrithiol (Scheme 16 (B)). In this
study, bicyclic peptides exhibited higher proteolytic stability
(trypsin) than monocyclic peptides and demonstrated promise
as antisense oligonucleotide delivery agents.[52]
Polyfluoroaromatics can conceptually undergo multiple
substitutions by peptide cysteines to afford for example tricyclic
systems.[40] However, due to the diminished reactivity of the
scaffold reagent following the first two substitutions, subse-
quent substitutions either proceed very slowly or tend not to
occur. Wu and co-workers addressed this using 2,3,5,6-tetra-
fluoroterephthalonitrile (66, Scheme 17).[53] Under mild aqueous
conditions, two para-fluoride groups are substituted readily by
thiols, followed by the slower substitution of the remaining two
fluorides. The differential reactivity for the second pair of
substitutions, as well as the lower nucleophilicity of penicill-
amine compared with cysteine (40-fold difference due to steric
hindrance by β-dimethyl substituents), was exploited to afford
sequential tetrasubstitutions, affording controlled access to
redox-stable tricyclic peptide systems containing two cysteine
and two penicillamine residues with high regiocontrol (only 2
isomers possible).
Scheme 16. Approaches to bicyclic peptide systems via perfluoroylation and subsequent macrocyclization. Based on Ref. [52].
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4. Summary and Outlook
Here we have briefly detailed some of the many reasons that
perfluoroaryl reagents occupy a prominent and growing space
in peptide and protein chemistry. They have applications in
peptide synthesis and bioconjugation, as well as potential
applications in tuning the properties of bioactive synthetic
peptides. The use of pentafluorophenyl esters of amino acids
for peptide synthesis is uncommon, however, the use of the
preformed activated esters provides the advantages of rapid
coupling reactions and the avoidance of bringing the growing
peptide chain into contact with the activating reagent, to
reduce side reactions.[19] This arguably provides better atom
economy as compared with excessive equivalents of activator
and additives. The clear disadvantage is the need to prepare
the pentafluorophenyl ester in advance, particularly for any
non-standard or synthesised amino acids.
In many ways perfluoroarylation bears the hallmark of a
‘click’ reaction, being rapid, quantitative and having a wide
functional group tolerance. Crosslinking of disulfides with
perfluoroaromatic reagents for example, hexafluorobenzene
gives predictable, highly regioselective substitution products
due to the directing effect of the α-carbanion-stabilising sulfur
atom from the initial substitution in the Meisenheimer
intermediate. They can be tuned to react with nitrogen and
oxygen-based nucleophiles to afford broader applications
compared with standard reagents that tend to be highly
specific to a particular nucleophile for example, maleimides,
sulfonyl fluorides or N-hydroxysuccinamide esters. In compar-
ison with other bioconjugation and crosslinking reagents, in
general perfluoroaromatics do not require the use of unnatural
amino acids containing for example, azides, alkynes or alkenes,
which can be expensive to purchase or tedious to synthesise.
Perfluoroaromatics react with natural amino acids to form
stable and non-reversible conjugates under physiological con-
ditions, unlike other reagents, such as maleimides.[54] Advanta-
geously, perfluoroaromatics afford the distinct ability to monitor
reactions and to identify substitution patterns around the
aromatic ring using 19F NMR.[35]
In general, perfluoroaromatic bioconjugation can enhance
the pharmacokinetic properties for example, serum stability and
conformational stability through stapling of bioactive synthetic
peptides (many examples above). However, perfluoroarylation
can add significant lipophilicity to a biomolecule and may affect
its solubility or cellular penetration in the case of for example,
stapled or macrocyclic peptides, albeit, this probably is more
dependent on the physicochemical properties of the starting
peptide. Crosslinking of native disulfides can also introduce
perturbation of native interactions and loss of pharmacological
activity,[55] which may be attributed to steric or conformational
deformation of the peptide, albeit this can be also true of
competitor approaches. Many simple perfluoroaromatics for
example, hexafluorobenzene, decafluorobiphenyl can have
poor solubility in water, requiring the use of organic co-
solvents, which may be incompatible with biomolecules, or the
augmentation of the reagent to include water-solubilising
motifs (e.g., sulfones),[56] which can also enhance the reaction
rates in water. Indeed, there are now many perfluoroaromatic
derivatives reported in the literature that have improved
reactivity profiles, broader nucleophile reactivity and compati-
bility with aqueous media.
From a reactivity point of view, mono-perfluoroarylation can
be difficult to achieve when there are multiple reactive
nucleophiles. This can be mitigated by using a large excess of
perfluoroaromatic reagent or the inclusion of a heteroatom as
in pentafluoropyridine. This increases the rate of mono-
substitution but the subsequent ‘para’-substitution cannot
occur. In practice, disubstituted perfluoroaromatics do not tend
to undergo further substitution by thiols under mild/physiolog-
ical conditions. However, as discussed above, this can poten-
tially happen with more highly activated systems, increasing
their metabolic liability, meaning that they may be subject to
further conjugation with for example glutathione in vivo and
may accelerate their degradation/excretion from the body.
Given that peptides can be readily and site-selectively
modified at a late stage by perfluoro(hetero)aryl reagents, this
will provide new opportunities for medicine and healthcare in
academia and pharma. The wide scope of nucleophiles that can
be used in combination with perfluoroaryls also lends them to
high-throughput screening applications. For example, using
complex mixtures of nucleophiles to rapidly generate com-
pound libraries at the early drug discovery stage; or different
size macrocycle screening are immediate opportunities. Given
the reversibility of tyrosine perfluoroarylation, this can be
Scheme 17. Precisely Regulated and Efficient (PROP) Locking of linear peptides containing differentially reactive nucleophiles (cysteine and penicillamine) into
tricyclic architectures using 2,3,5,6-tetrafluoroterephthalonitrile. Note, peptide sequences shown are for illustrative purposes only. Based on Ref. [53].
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optimised and exploited as a prodrug strategy to increase for
example cell membrane permeability or to allow access to the
BBB. Glimpses of the possible ability of fluoroarylation, either
directly, or as an intermediary, to modulate ‘drug-like’ proper-
ties, such as blood serum stability and blood-brain barrier
penetration is likely to promote a significant new tool for lead-
optimisation. Reactivity-tuned fluoroarylated peptides may
afford new warheads for highly targeted covalently reactive
enzyme inhibitors, which have risen to prominence, specifically
in the protein kinases field and may be employed in the
emerging covalent PROTACs area. Given their biocompatibility,
fluoroaromatic probes may also find applications as diagnostic
agents for ex vivo 19F NMR analysis of primary patient samples
to monitor biomarkers of disease. Moreover, [18F]-fluoroaro-
matics may provide a new strategy for radiolabelling of
peptides and proteins for personalised PET tracers, given their
rapid and clean reactivity, which is well suited to the short
radiochemical half-life of 18F.[57]
From a purely chemical synthesis perspective the use of
perfluoroaryl reagents offers an exciting avenue to deliver new
molecular functionality. The ease and simplicity with which
perfluoroaryl reagents can link together disparate molecular
units gives these reagents a distinct advantage over more
complex methodologies such as cross coupling. The use of
these reagents for molecular linkage bares similarity to the use
of copper-catalysed azide-alkyne cycloadditions (CuAAC) to
access 1,2,3-triazoles in “click chemistry” as both are quick and
efficient linkage manifolds. Being able to exploit this reactivity
in combination with the ability for these reactions to be
reversed (not possible with CuAAC) could lead perfluoroaryl
reagents to become a valuable tool in dynamic molecular
linkage.
In conclusion, perfluoroaromatics and perfluoroheteroaro-
matic regents have been demonstrated to allow access to
modified peptides and as highly efficient bioconjugation
reagents. This area is an exciting and rapidly growing one with
many future avenues for further exploitation. These reagents
offer a new and easy to use toolbox to both peptide and
synthetic chemists for molecular diversification and modifica-
tion.
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Perfluoroaromatic and perfluoroheter-
oaromatic reagents have emerged in
recent years as powerful reagents for
peptide and protein modification.
Dominated by their regio- and che-
moselective nucleophilic aromatic
substitution chemistry under mild
conditions, they have been used in
peptide synthesis, tagging, cyclisation,
stapling and protein bioconjugation.
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